Skip to main content
SpringerLink
Log in

CCRK—a hub for liver metastasis and cancer

  • Comment
  • Published:
Cellular & Molecular Immunology Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Golubnitschaja, O. & Sridhar, K. C. Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes. Clin. Exp. Metastasis 33, 743–755 (2016).

    Article  CAS  Google Scholar 

  2. Agarwala, S. S., Eggermont, A. M., O’Day, S. & Zager, J. S. Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. Cancer 120, 781–789 (2014).

    Article  Google Scholar 

  3. Valderrama-Trevino, A. I., Barrera-Mera, B., Ceballos-Villalva, J. C. & Montalvo-Jave, E. E. Hepatic metastasis from colorectal cancer. Euroasian J. Hepatogastroenterol 7, 166–175 (2017).

    Article  Google Scholar 

  4. Zeng, X. et al. Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. Cell Mol. Immunol. https://doi.org/10.1038/s41423-020-00534-2 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249–252 (2019).

    Article  CAS  Google Scholar 

  6. Feng, H. et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. J. Clin. Invest 121, 3159–3175 (2011).

    Article  CAS  Google Scholar 

  7. Yu, Z. et al. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis. Gut 63, 1793–1804 (2014).

    Article  CAS  Google Scholar 

  8. Feng, H. et al. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients. J. Hepatol. 62, 1100–1111 (2015).

    Article  CAS  Google Scholar 

  9. Mok, M. T. et al. CCRK is a novel signalling hub exploitable in cancer immunotherapy. Pharm. Ther. 186, 138–151 (2018).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from the Ministry of Science and Technology (MOST 108-2314-B-194-003-MY2).

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan, China

    Jie-Ting Low, Guan-Ling Lin & Michael W. Y. Chan

  2. Epigenomics and Human Disease Research Center, National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan, China

    Jie-Ting Low, Guan-Ling Lin & Michael W. Y. Chan

  3. Center for Innovative Research on Aging Society (CIRAS), National Chung Cheng University, Min-Hsiung, Chia-Yi, Taiwan, China

    Michael W. Y. Chan

Authors
  1. Jie-Ting Low
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guan-Ling Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael W. Y. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. Y. Chan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Low, JT., Lin, GL. & Chan, M.W.Y. CCRK—a hub for liver metastasis and cancer. Cell Mol Immunol 18, 1341–1342 (2021). https://doi.org/10.1038/s41423-020-00569-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-020-00569-5

  • Springer Nature Limited

Search

Navigation